ReviewAnnual review of pharmacology and toxicology2015
Improving postapproval drug safety surveillance: getting better information sooner.
Review in Annual review of pharmacology and toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A review on adverse drug reaction related to medication in health sector: an account of what we have discovered and implemented-pharmacovigilance.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Predicting Drug Blood-Brain Barrier Penetration with Adverse Event Report Embeddings.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022Article
- Data Mining for Adverse Events of Tumor Necrosis Factor-Alpha Inhibitors in Pediatric Patients: Tree-Based Scan Statistic Analyses of Danish Nationwide Health Data.Clinical drug investigation · 2020Article
- Building a framework for the evaluation of knowledge translation for the Canadian Network for Observational Drug Effect Studies.Pharmacoepidemiology and drug safety · 2020Article
- Advancing regulatory science and assessment of FDA REMS programs: A mixed-methods evaluation examining physician survey response.Journal of clinical and translational science · 2019Article
- Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database.Open access journal of contraception · 2018Article
- Personalized medicine: Genetic risk prediction of drug response.Pharmacology & therapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Adverse drug events (ADEs) are an important public health concern, accounting for 5% of all hospital admissions and two-thirds of all complications occurring shortly after hospital discharge. There are often long delays between when a drug is approved and when serious ADEs are identified. Recent and ongoing advances in drug safety surveillance include the establishment of government-sponsored networks of population databases, the use of data mining approaches, and the formal integration of diverse sources of drug safety information. These advances promise to reduce delays in identifying drug-related risks and in providing reassurance about the absence of such risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.